Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients

Launched by DAMANHOUR UNIVERSITY · Aug 22, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how a supplement called Coenzyme Q10 might help reduce side effects caused by a chemotherapy drug called paclitaxel in women with breast cancer. The goal is to see if Coenzyme Q10 can make the treatment easier for patients by preventing or lessening these side effects, known as chemotherapeutic toxicity.

To participate in this study, women must be at least 18 years old and newly diagnosed with breast cancer, meaning they have not yet started chemotherapy. They should have a performance level that allows them to carry out daily activities with some minor limitations. However, women with certain health issues, such as advanced liver or kidney disease, or those who are pregnant or breastfeeding, cannot join the trial. If eligible, participants can expect to receive either Coenzyme Q10 or a placebo (a harmless sugar pill) during the study and will be monitored for any changes in their symptoms and overall well-being. This research is currently recruiting participants, and it aims to provide valuable information on managing the side effects of breast cancer treatment.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. women with newly diagnosed breast cancer r ≥18 years old.
• • 2. Naive to chemotherapy.
• • 3. Eastern Cooperative Oncology Group (ECOG) performance status from 0-2
• Exclusion Criteria:
• • 1. Advanced liver disease (defined as liver enzyme elevation \>3-fold upper limit of normality, or cirrhosis); chronic kidney disease (CKD, defined as an estimated glomerular filtration rate (eGFR) \<60 ml min-1 1.73 m-2).
• • 2. Patients with a history of allergy to Coenzyme Q10 and similar compounds.
• • 3. Concomitant use of opioids, anticonvulsants, tricyclic antidepressants, other neuropathic pain medication.
• • 4. Pregnancy or breast feeding.
• • 5. hereditary muscle disorders.